Management and Board change

RNS Number : 1853X
Oxford Biomedica PLC
10 February 2012
 

 

 

 

 

 

 

Oxford BioMedica plc

Management and Board change

 

-- Appointment of new Chief Financial Officer and Company Secretary --

 

Oxford, UK - 10 February 2012: Oxford BioMedica ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, today announces that Andrew Wood, Chief Financial Officer, has stepped down from the Board of Oxford BioMedica.  Tim Watts has been appointed to the Board as Chief Financial Officer and Company Secretary of Oxford BioMedica with immediate effect.  Andrew will continue as an employee of the Company for the time being to ensure the smooth transition of the role.

 

Tim is a senior financial executive with over 30 years' experience in leading multinational and entrepreneurial businesses.  He was most recently Chief Financial Officer at Archimedes Pharma Ltd., an international specialty pharmaceutical company.  Tim qualified as a chartered accountant, beginning his career with Coopers & Lybrand before moving to H J Heinz, the food producer.  In 1985 Tim joined ICI, initially in the corporate headquarters and from 1990 in the pharmaceuticals division, eventually rising to be Finance Director of the Zeneca Pharmaceuticals business.  Following the merger of Astra and Zeneca, Tim became Group Financial Controller of AstraZeneca PLC in 2001.  In 2007 he left AstraZeneca to become Chief Financial Officer at Archimedes Pharma.  Tim has a proven track record in the industry, including managing corporate transactions, M&A activity, fundraising and strategic implementation.

 

John Dawson, Chief Executive Officer of Oxford BioMedica, said: "We thank Andrew for his substantial contribution to Oxford BioMedica since its IPO in 1996.  His commitment to the Company has been invaluable and we wish him well for the future.  I would like to welcome Tim to the executive management team and am confident that his expertise will support Oxford BioMedica's strategy to secure corporate and commercial success."

 

There is no other information to be disclosed under Paragraph 9.6.13 R of the Listing Rules.

 

-Ends-




 

For further information, please contact:


Oxford BioMedica plc:

Lara Mott, Head of Corporate Communications

Tel: +44 (0)1865 783 000

 

Media Enquiries:

Mary Clark/Claire Dickinson

M:Communications

 

Tel: +44 (0)20 7920 2342

 

 

Notes to editors

 

1. Oxford BioMedica®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs.  The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy.  Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, VIRxSYS, Emergent BioSolutions and ImaginAb. Further information is available at www.oxfordbiomedica.co.uk.


This information is provided by RNS
The company news service from the London Stock Exchange
 

END

 
 

BOAZMGMZVGRGZZG